ClinicalTrials.Veeva

Menu

Auricular Vagus Nerve Stimulation (aVNS) in Chronic Spinal Cord Injuries (SCI)

University of Miami logo

University of Miami

Status

Enrolling

Conditions

Spinal Cord Injuries

Treatments

Device: sham aVNS
Device: auricular nerve stimulation (aVNS)

Study type

Interventional

Funder types

Other
Other U.S. Federal agency

Identifiers

NCT06588608
20240490

Details and patient eligibility

About

The purpose of this research is to test if Auricular Vagal Nerve Stimulation (aVNS) is safe in persons with spinal cord injury (SCI).

Enrollment

16 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Males and females
  2. Chronic (equal or greater to 1 year) motor-complete and incomplete SCI Abbreviated Injury Scale (AIS) of A or B at the C5-T10 levels

Exclusion criteria

  1. Pregnant or breastfeeding
  2. Prisoner
  3. Failure to satisfy inclusion criteria
  4. Previous bariatric surgery
  5. Active implantable devices (such as pacemakers)
  6. Skin irritation or damage at the site (ear)

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

16 participants in 2 patient groups

aVNS followed by no aVNS in subjects with SCI
Experimental group
Description:
Auricular vagal nerve stimulation (aVNS) will be provided by a device that is placed around the ear. A low-voltage electrical signal will be given for 30 minutes. In the following visit, subjects will complete all study assessments without the aVNS. Participation will be up to 2 weeks.
Treatment:
Device: auricular nerve stimulation (aVNS)
Device: sham aVNS
no aVNS followed by aVNS in subjects with SCI
Experimental group
Description:
Subjects will complete all study assessments without the aVNS. In the following visit, Auricular vagal nerve stimulation (aVNS) will be provided by a device that is placed around the ear. A low-voltage electrical signal will be given for 30 minutes. Participation will be up to 2 weeks.
Treatment:
Device: auricular nerve stimulation (aVNS)
Device: sham aVNS

Trial contacts and locations

1

Loading...

Central trial contact

Patricia Graham, MS, CCRC; Patrick D Ganzer, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems